全国同城凤凰楼信息茶楼_51pcmc品茶2024官网_全国兼职凤凰楼信息

Dr. Luo comprehensively applied theoretical methods including computational biology, bioinformatics, and drug design, combined with various chemical biology validation platforms, to discovery innovative drugs that target novel targets, mainly aimed at epigenetic enzymes and protein-protein interactions, or innovative drugs with novel mechanisms, and also investigate the mechanisms of these drugs. With these strategies, the regulatory mechanism of several important targets were revealed, and a bunch of lead compounds with development prospect were discovered (5 categories for the first time in the world), and two compounds are under clinical trials. More than 240 SCI papers were published, with a total impact factors above 1600, around 10000 citations by others, and the H-index is 47. In the past five years, breakthroughs were published on Nature, Nature Chem, JACS, PNAS, Adv Mater, Nucleic Acids Res, J Med Chem and other famous international journals as corresponding, co-corresponding or first author. 19 patent applications (2 PCT) have been submitted, and 3 domestic and 1 U.S patent applications were granted with a license. 18 graduate students graduated from his lab, and CAS Dean Excellence Award was conferred once, Excellent Graduation Thesis of Shanghai was conferred once, National Award for Graduates was conferred 10 times.

EDUCATION

09/1990-07/1994 Fuzhou University, Department of Chemistry, Bachelor Degree for Structural Chemistry

09/1998-07/2001 Fudan University, Department of Chemistry, Master Degree for Physical Chemistry

09/2001-07/2004 Shanghai Institute of Materia Medica, Ph.D Degree for Organic Chemistry

WORK EXPERIENCE

10/1994-05/1998 Assistant Engineer, Fuzhou Antibiotic Co. Ltd.

07/2004-09/2005 Assistant Professor, Shanghai Institute of Materia Medica, Drug Design

09/2005-03/2008 Postdoctoral Fellow, Ronen Marmorstein Lab, Wistar Institute, University of Pennsylvania, Epigenetics and Chemical Biology

03/2008-10/2008 Assistant Professor, Shanghai Institute of Materia Medica, Drug Design and Chemical Biology

10/2008-10/2012 Associate Professor, Shanghai Institute of Materia Medica, Drug Design and Chemical Biology

10/2012-Present Professor, Shanghai Institute of Materia Medica, Drug Design and Chemical Biology

1. Computational drug design

2.Medicinal chemical biology

3.Medicinal chemistry

Dr. Luo’s research field is drug design and chemical biology, his research interests focus on the discoveries of new drug targets of natural products and metabolites as well as the mechanisms of the regulations of the targets using multidisciplinary technologies in biochemistry, structural biology and medicinal chemical biology. Dr. Luo has discovered targets of many important natural products or endogenous metabolites, and revealed the regulation mechanisms of the important targets. In addition, he also developed a series of promising lead compounds including the copper transporter inhibitor DC-AC50 and the small G protein Rho subfamily inhibitor DC-Rhoin. Among them 3 compounds are in pre-clinical evaluation and some compounds have been transferred successfully. Dr. Luo has published more than 130 peer-viewed paper including Nature, Cancer Cell, Nat. Chem., Adv. Sci., JACS, PNAS, Nucleic Acid Res. with about 10000 citations. He also applied 56 patents and 5 of them have been authorized and transferred successfully. Dr. Luo has presided over more than 10 projects, such as the "863" project, the key projects of the National Natural Science Foundation of China and Distinguished Young Scholars Fund Project. Dr. Luo has also received many honors, including leader in innovation of the Ministry of Science and Technology, leader in the "Ten Thousand Talents Program" of the Organization Department of the Central Committee, and an outstanding academic leader in Shanghai. Dr. Luo has trained more than 50 graduate students, some of whom have been engaged in post-doctoral research in the world-famous universities such as Harvard University, University of Chicago, University of Pennsylvania, European Center for Molecular Biology, and some of whom have been funded by a number of talent programs including the Hundred Talents Program of the Chinese Academy of Sciences.

1.Lulu Hu#, Junyan Lu#, Jingdong Cheng#, Qinhui Rao, Ze Li, Haifeng Hou, Zhiyong Lou, Lei Zhang, Wei Li, Wei Gong, Mengjie Liu, Chang Sun, Xiaotong Yin, Jie Li, Xiangshi Tan, Pengcheng Wang, Yinsheng Wang, Dong Fang, Qiang Cui, Pengyuan Yang, Chuan He, Hualiang Jiang, Cheng Luo* and Yanhui Xu*, Structural Insight into Substrate Preference for TET-mediated Oxidation. Nature 2015;527(7576):118-22.

2.Jing Wang#, Cheng Luo#（co-first）, Changliang Shan#, Qiancheng You#, Junyan Lu Shannon Elf, Yu Zhou, Yi Wen, Yuxin Xie, Jan L Vinkenborg, Jun Fan, Heebum Kang, Dali Han, Jason Karpus, Shijie Chen, Shisheng Ouyang, Chihao Luan, Naixia Zhang, Maarten Merkx, Hong Liu, Jing Chen*, Hualiang Jiang*, Chuan He*, Inhibition of human copper trafficking significantly attenuates tumor growth. Nature Chem 2015; 7(12):968-79.

3.Junyan Lu, Chenxiao Jianga, Xiaojing Lia, Lizhi Jiang, Zengxia Li, Tilman Schneider-Poetsch, Kunqian Yu, Jun O. Liu, Hualiang Jiang, Cheng Luo*, Yongjun Dang*. The Inter-domain Linker of eIF4AI Regulates ATP Hydrolysis Coupled Duplex Unwinding, Nucleic Acids Res 2015;. pii: gkv1033.

4.Fanwang Meng, Sufang Cheng, Hong Ding, Shien Liu, Ying Liu, Kongkai Zhu, Shijie Chen, Junyan Lu, Yiqian Xie, Linjuan Li, Rongfeng Liu, Zhe Shi, Yu Zhou, Yu-Chih Liu, Mingyue Zheng, Hualiang Jiang, Wencong Lu*, Hong Liu*, and Cheng Luo*. Discovery and optimization of novel, selective histone methyltransferase SET7 inhibitors by pharmacophore- and docking-based virtual screening. J Med Chem, 2015; 58(20):8166-81.

5.Xiangqian Kong, Jian Liu, Lianchun Li, Liyan Yue, Lihong Zhang, Hualiang Jiang, Xin Xie*, Cheng Luo*, Functional Interplay Between the RK motif and Linker Segment Dictates Oct4-DNA Recognition, Nucleic Acids Res 2015;43(9):4381-92.

6.Yue Huang, Jingli Yan, Qi Li, Jiafei Li, Shouzhe Gong, Hu Zhou, Jianhua Gan, Hualiang Jiang, Gui-Fang Jia*, Cheng Luo*, and Cai-Guang Yang* Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acid Res 2015; 43(1):373-84.

7.Xiangqian Kong, Limin Chen, Lianying Jiao, Xiangrui Jiang, Fulin Lian, Junyan Lu, Kongkai Zhu, Daohai Du, Jingqiu Liu, Hong Ding, Naixia Zhang, Jingshan Shen, Mingyue Zheng, Kaixian Chen, Xin Liu, Hualiang Jiang and Cheng Luo*. Astemizole Arrests the Proliferation of Cancer Cells by Disrupting the EZH2-EED Interaction of Polycomb Repressive Complex 2. J Med Chem, 2014; 57:9512-21.

8.Shijie Chen, Yulan Wang, Wen Zhou, Shanshan Li, Jianlong Peng, Zhe Shi, Junchi Hu, Yu-Chih Liu, Hong Ding, Yijyun Lin, Linjuan Li, Sufang Cheng, Jingqiu Liu, Tao Lu, Hualiang Jiang, Bo Liu*, Mingyue Zheng* and Cheng Luo*. Identifying Novel Selective Non-Nucleoside DNA Methyltransferase 1 Inhibitors through Docking-Based Virtual Screening. J Med Chem, 2014;57,9028-41.

9.Jie Zhang, Hongchuan Liu, Kongkai Zhu, Shouzhe Gong, Shaynoor Dramsi, Ya-Ting Wang, Jiafei Li, Feifei Chen, Ruihan Zhang, Lu Zhou, Lefu Lan, Hualiang Jiang, Olaf Schneewind*, Cheng Luo*, Cai-Guang Yang*. Antiinfective therapy with a small molecule inhibitor of Staphylococcus aureus sortase. P Natl Acad Sci 2014;111(37):13517-22.

10.Yifan Jiang, Junyan Lu, Yaping Wang, Feng Zeng, Huiyuan Wang, Huige Peng, Min Huang, Hualiang Jiang, Cheng Luo* and Yongzhuo Huang*. Molecular Dynamic Simulation-driven Design of Protease-responsive Probe for in vivo Tumor Imaging. Adv Mater 2014;26(48):8174-8.